Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.
about
Targeting gastrointestinal stromal tumors: the role of regorafenibPhase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.Targeted therapy for cancer: the gastrointestinal stromal tumor model.Is there something other than imatinib mesilate in therapeutic options for GIST?A gist of gastrointestinal stromal tumors: A review.A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutationsAntitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cellsNilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.National trends in spending on and use of oral oncologics, first quarter 2006 through third quarter 2011.Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors.Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trialGastrointestinal stromal tumors: management of metastatic disease and emerging therapies.Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT InhibitionCalcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers.Surgical resection of recurrent gastrointestinal stromal tumor after interruption of long-term nilotinib therapy.Recent advances in the treatment of gastrointestinal stromal tumors.Extra-gastrointestinal stromal tumor of the pancreas: case report and review of the literature.A potential role for nilotinib in KIT-mutated melanoma.Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization.Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy.Nilotinib for treatment of gastrointestinal stromal tumors: out of the equation?Treatments for gastrointestinal stromal tumors that are resistant to standard therapies.Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review.An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients.Pneumatosis intestinalis during chemotherapy with nilotinib in a patient with chronic myeloid leukemia who tested positive for anti-topoisomerase I antibodies.Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma.Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors.Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches.
P2860
Q26747162-BD44CBC3-90B6-4974-9B7A-18A616AC7FA4Q33410655-86B836EC-E18B-4487-8B7D-590D6A93DB7AQ33807742-CB7C80CD-2A00-4062-8A2E-86E9B124C1AEQ34207379-99A86AE8-E129-4A8F-BF55-19C620E5C4D8Q34654203-46985BF9-5DAC-4927-8668-C7A8C9B9DBD0Q34737119-01DB39B4-1206-43F9-B7DC-56BA8D9943E4Q34804754-154919DC-C34B-4251-AD2C-F2814353C231Q35252470-97414D09-5ECB-4330-AC86-01EA3C04B4C9Q35905878-3E15E2E4-2F6A-4B3A-B46E-95CCEB56448FQ36125906-53163B91-68E9-4DA1-93E1-3C6C71FA310DQ36125976-878861EE-B81A-4FC4-B5F7-E8B50FA37BBCQ36180074-5E349913-AA4E-4890-B2A4-F337C253D446Q36910431-9997B68B-0DB6-47B0-ACE3-B85748A1543AQ37220191-68329446-8623-45A5-BE4E-E88E4BB0E57BQ37237619-E46A6791-74BC-46DE-984D-B9849FDD93CFQ37281684-4386590D-7D62-4043-AC16-BB036884B857Q37423620-CD83FE96-F73C-4835-83D5-2FE744D92D76Q37704347-715D9F11-F7C1-456A-AA62-BBAAF9C98ADDQ37724926-9AE0841E-4DC1-49EE-B202-A49368335E92Q38002439-C7DA4083-43BB-47C1-8CE9-9E62E33519BEQ38067464-32254E6B-C55E-483A-B681-627584633F38Q38112821-D789F68C-143C-4E2B-A527-A775D1E634B8Q38120079-213ACDC6-B364-4A4E-A9E9-35B27102C19DQ38268165-19BDEE41-F88A-44D0-A202-DDF52F3D31E5Q38527941-8FB0C30B-C859-4F58-979D-D96873F706EBQ38869809-B4AE084D-6976-41BD-9B07-DF985DD68D7DQ38957115-41AC540D-9016-404A-9750-9D1E892D3542Q39167351-7D053B63-C927-47BA-B9BB-B35B3E5EBFA0Q39453613-BE317D18-ADC4-473D-9177-9EECA6B7D035Q40567012-4075307A-40B2-457D-B5EF-47516FDDBD4DQ49244147-EA404F51-B555-4CDA-A33F-6D0FD55E99B6Q53390220-5CF3BE23-64A6-4B03-9B65-3253402434FAQ54113454-F925B98D-DC19-40D2-91A8-D11BD1B80B07Q54863183-0788B59C-846A-4E1D-85B2-6F4FC5A476B5
P2860
Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Phase 2 study of nilotinib as ...... astrointestinal stromal tumor.
@en
Phase 2 study of nilotinib as ...... astrointestinal stromal tumor.
@nl
type
label
Phase 2 study of nilotinib as ...... astrointestinal stromal tumor.
@en
Phase 2 study of nilotinib as ...... astrointestinal stromal tumor.
@nl
prefLabel
Phase 2 study of nilotinib as ...... astrointestinal stromal tumor.
@en
Phase 2 study of nilotinib as ...... astrointestinal stromal tumor.
@nl
P2093
P2860
P356
P1433
P1476
Phase 2 study of nilotinib as ...... astrointestinal stromal tumor.
@en
P2093
Akira Sawaki
Atsushi Ohtsu
Makoto Yamasaki
Tatsuo Kanda
Toshirou Nishida
Yasuhide Yamada
Yoshihiro Kakeji
Yoshito Komatsu
Yusuke Onozawa
P2860
P304
P356
10.1002/CNCR.26120
P407
P577
2011-03-31T00:00:00Z